Radiation therapy for prostate cancer after prostatectomy: Adjuvant or salvage?

Nature Reviews Urology

Volumn 8, Issue 7, 2011, Pages 385-392

  Patel, Amit R ^a   Stephenson, Andrew J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL RECURRENCE; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROCTITIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REVIEW; RISK FACTOR; RISK REDUCTION; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; URINE INCONTINENCE;

ANIMALS; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; TIME FACTORS;

EID: 79960246597     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.80     Document Type: Review

References (58)

1. Burkhardt, J. H. et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J. Clin. Oncol. 20, 2869-2875 (2002). (Pubitemid 34651516)
2. Stephenson, A. J. et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Natl Cancer Inst. 98, 715-717 (2006). (Pubitemid 43821789)
3. Vickers, A. J. et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J. Natl Cancer Inst. 99, 1171-1177 (2007). (Pubitemid 47233067)
4. Moul, J. W. Prostate specific antigen only progression of prostate cancer. J. Urol. 163, 1632-1642 (2000). (Pubitemid 30366704)
5. Kupelian, P. A. et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J. Clin. Oncol. 20, 3376-3385 (2002).
6. Pound, C. R., Partin, A. W., Epstein, J. I. & Walsh, P. C. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. North Am. 24, 395-406 (1997).
7. Patel, A., Dorey, F., Franklin, J. & deKernion, J. B. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J. Urol. 158, 1441-1445 (1997). (Pubitemid 27391215)
8. Roberts, S. G. et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin. Proc. 76, 576-581 (2001).
9. Ornstein, D. K. et al. Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 52, 1047-1054 (1998). (Pubitemid 28533375)
10. Bill-Axelson, A. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352, 1977-1984 (2005). (Pubitemid 40638368)
11. Lightner, D. J., Lange, P. H., Reddy, P. K. & Moore, L. Prostate specific antigen and local recurrence after radical prostatectomy. J. Urol. 144, 921-926 (1990). (Pubitemid 20324820)
12. Leventis, A. K., Shariat, S. F. & Slawin, K. M. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219, 432-439 (2001). (Pubitemid 32336357)
13. Raj, G. V., Partin, A. W. & Polascik, T. J. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94, 987-996 (2002). (Pubitemid 34150853)
14. Sella, T. et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231, 379-385 (2004). (Pubitemid 38552892)
15. Stephenson, A. J. et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291, 1325-1332 (2004). (Pubitemid 38541647)
16. Stephenson, A. J. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol. 25, 2035-2041 (2007). (Pubitemid 46972788)
17. Stephenson, A. J. & Slawin, K. M. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy. Nat. Clin. Pract. Urol. 1, 90-96 (2004). (Pubitemid 40823734)
18. Katz, M. S. et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J. Clin. Oncol. 21, 483-489 (2003). (Pubitemid 46606478)
19. Swanson, G. P. et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J. Clin. Oncol. 25, 2225-2229 (2007). (Pubitemid 46954647)
20. Thompson, I. M. et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181, 956-962 (2009).
21. Bolla, M. et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366, 572-578 (2005). (Pubitemid 41140332)
22. Wiegel, T. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27, 2924-2930 (2009).
23. MacDonald, O. K. et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology 64, 760-764 (2004). (Pubitemid 39446058)
24. Trock, B. J. et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299, 2760-2769 (2008). (Pubitemid 351846851)
25. Messing, E. M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 341, 1781-1788 (1999).
26. Messing, E. M. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 7, 472-479 (2006). (Pubitemid 43779173)
27. Eggener, S. E. et al. Predicting prostate cancer-specific mortality after radical prostatectomy based on the pathological features of prostate cancer. J. Urol. 185, 869-875 (2011).
28. Schroder, F. H. et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J. Urol. 172, 923-927 (2004). (Pubitemid 39096424)
29. Schroder, F. H. et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur. Urol. 55, 14-22 (2009).
30. Bolla, M. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103-106 (2002).
31. Shipley, W. U. et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281, 1598-1604 (1999). (Pubitemid 29211768)
32. Hanks, G. E. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol. 21, 3972-3978 (2003). (Pubitemid 46606211)
33. Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516-2527 (2009).
34. Da Pozzo, L. F. et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur. Urol. 55, 1003-1011 (2009).
35. Potosky, A. L. et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J. Natl Cancer Inst. 94, 430-437 (2002). (Pubitemid 34285092)
36. Smith, M. R. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 97 (Suppl. 3), 789-795 (2003). (Pubitemid 36125814)
37. DAmico, A. V. et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 25, 2420-2425 (2007).
38. Berry, D. A. et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353, 1784-1792 (2005). (Pubitemid 41549890)
39. Krook, J. E. et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324, 709-715 (1991).
40. Pound, C. R. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591-1597 (1999). (Pubitemid 29211767)
41. Anscher, M. S. Salvage radiotherapy for recurrent prostate cancer: the earlier the better. JAMA 291, 1380-1382 (2004). (Pubitemid 38541653)
42. Anscher, M. S. Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen. Int. J. Cancer 96, 91-93 (2001). (Pubitemid 32291428)
43. Trabulsi, E. J. et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 72, 1298-1304 (2008).
44. Taylor, N. et al. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 56, 755-763 (2003). (Pubitemid 36677369)
45. Valicenti, R. K. et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int. J. Radiat. Oncol. Biol. Phys. 45, 53-58 (1999). (Pubitemid 29380074)
46. Anscher, M. S., Robertson, C. N. & Prosnitz, R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. Int. J. Radiat. Oncol. Biol. Phys. 33, 37-43 (1995).
47. Catton, C. et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother. Oncol. 59, 51-60 (2001). (Pubitemid 32261076)
48. Stephenson, A. J. et al. Location, extent, and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy compared to their presence or absence. J. Urol. 182, 1357-1363 (2009).
49. Bianco, F. J. Jr, Scardino, P. T. & Eastham, J. A. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (trifecta). Urology 66 (Suppl. 5), 83-94 (2005). (Pubitemid 41356564)
50. Hull, G. W. et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J. Urol. 167 (2 Pt 1), 528-534 (2002). (Pubitemid 34074521)
51. Thompson, I. M. Jr et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296, 2329-2335 (2006). (Pubitemid 44749360)
52. Van Poppel, H. et al. Adjuvant radiotherapy after radical prostatectomy in patients with pathologically high risk prostate cancer: 10-Year follow-up results. Eur. Urol. Suppl. 10, 93 (Abstract 227) (2011).
53. Van Cangh, P. J. et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J. Urol. 159, 164-166 (1998). (Pubitemid 27525595)
54. Van der Kwast, T. H. et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J. Clin. Oncol. 25, 4178-4186 (2007). (Pubitemid 47548556)
55. Cox, J. D. et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J. Clin. Oncol. 17, 1155 (1999).
56. Stephenson, A. J. et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 23, 7005-7012 (2005).
57. Brenner, D. J., Curtis, R. E., Hall, E. J. & Ron, E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88, 398-406 (2000). (Pubitemid 30051826)
58. Moon, K., Stukenborg, G. J., Keim, J. & Theodorescu, D. Cancer incidence after localized therapy for prostate cancer. Cancer 107, 991-998 (2006). (Pubitemid 44291148)